%20(5).jpg)
.jpg)
%20(3).jpg)
Big achievement of Bharat Biotech, clinical trial of TB vaccine on adults started in India
A clinical trial of the Tuberculosis vaccine MTBVac has started on adults in India. Bharat Biotech International Limited gave this information on Sunday. MountBvac is being developed for two purposes, the release said. The first would be a more effective and potentially longer-lasting vaccine than BCG (Bacillus Calmette Guerin) for newborns.
In India, a clinical trial for the Mtbvac vaccine against tuberculosis has begun. This will be the first-ever vaccine against tuberculosis produced by Spanish biopharmaceutical company Biofabri from a human source. This information was released on Sunday by Bharat Biotech International Limited.
According to the release, MountBvac is being developed for two purposes. The first would be a vaccine for babies that is both more potent and might last longer than BCG (bacillus Calmette Guerin). However, it will be for the prevention of tuberculosis in adults and adolescents, for which there is currently no effective vaccine.
These trials have been conducted by Bharat Biotech in collaboration with Biofabri. Trials to evaluate the safety and immunogenicity of MTBVac have begun with a pivotal safety, immunogenicity and efficacy trial. It is planned to start by 2025.
